血必净治疗重度慢性阻塞性肺病急性发作临床疗效分析  

Clinical Efficacy Analysis of Xuebijing Injection Used for Treatment of Acute Attack of Severe Chronic Obstructive Pulmonary Disease

作　　者：柏山[1] 

机构地区：[1]扬州市第一人民医院重症医学科,2250001

出　　处：《黑龙江医药》2013年第6期1187-1188,共2页Heilongjiang Medicine journal

摘　　要：目的:观察血必净注射液治疗重症慢性阻塞性肺病的临床疗效和安全性。方法:将100例重症慢性阻塞性肺病患者随机分为治疗组和对照组,对照组给予常规抗感染、祛痰、吸氧、有创及无创呼吸机支持及对症支持治疗,治疗组在常规治疗基础上加用血必净注射液100ml/天,静脉滴注,连用14天。比较两组治疗前后临床症状、白细胞总数、体温、PO2、SaO2,及PaO2/FiO2变化,并检测治疗前后的肝肾功能、血小板变化。结果:治疗组总有效率96.4%,对照组总有效率71.43%,两组差异有显著性(P<0.05),平均住院日治疗组[(18.32±7.32)天]与对照组[(23.00±7.04)天]比较差异有显著性(P<0.05)。治疗组治疗后3天和7天的体温、白细胞总数,ICU住院时间,PO2,SaO2,PaO2/FiO2,与对照组相比差异有显著性(P<0.05),两组治疗前后肝肾功能、血小板计数差异无显著性(P>0.05)。结论:血必净注射液治疗重症慢性阻塞性肺病具有较好的临床疗效和安全性。Objective：To observe clinical efficacy and Security of Xuebijing Injection used for treatment of acute attack of severe chronic obstructive pulmonary disease. Methods：100 patients with severe chronic obstructive pulmonary disease （COPD） patients were randomly divided into a treatment group and a control group, the control group received conventional anti-infective, expectorant,＆nbsp;oxygen, invasive and non-invasive ventilator support and symptomatic and supportive treatment, the treatment group were treated based on the addition of Xuebijing injection 100ml/day, intravenous infusion, once every 14 days. The clinical symptoms were compared before and after treatment, the total number of white blood cells, the body temperature, PO2, SaO2, and PaO2/FiO2 changes and detection of liver and kidney function before and after treatment, platelet changes. Results：the treatment group was 96.4%, the total efficiency of 71.43%of the control group, the difference between the two groups was significant （P0.05）. Conclusion：Xuebijing to injection in the treatment of severe chronic obstructive pulmonary disease（COPD） have better clinical efficacy and safety.

关 键 词：血必净注射液 重症 慢性阻塞性肺病 

分 类 号：R563[医药卫生—呼吸系统]